Comphya Welcomes Pim van Wesel as Advisor to the Board of Directors

PRESS RELEASE

Lausanne, Switzerland – March 06, 2025 – Comphya SA, a leading innovator in medical technology for erectile dysfunction solutions, is delighted to announce the appointment of Pim van Wesel as Advisor to the Board of Directors. Pim brings a wealth of experience in life sciences, having held senior and global leadership positions at world-class MedTech companies, including Medtronic and BD.

A seasoned life sciences executive with a proven track record in innovative therapy development and commercialization, Pim currently serves as Vice President & General Manager for the former AMF Medical product development operations, which he successfully led as Co-CEO. Under his leadership, AMF Medical transitioned out of stealth mode, secured multiple funding rounds, obtained Breakthrough Device Designation, and was ultimately acquired by Tandem Diabetes Care in 2023.

Throughout his career, Pim has been dedicated to therapy adoption for better patient outcomes, caregiver success, and efficiency, driving positive healthcare impact. He has achieved business success through insightful strategy formulation and execution, leveraging high-performance teams built with his engagement-driven and execution-oriented leadership mindset.

His background also includes relevant experience in neuromodulation within the urology field, making his expertise particularly valuable for Comphya. In his role as Advisor to the Board, Pim will support Comphya’s strategic initiatives, clinical and regulatory advancements, and fundraising efforts.

Pim van Wesel shared his enthusiasm, stating, “Comphya is developing a groundbreaking technology that has the potential to redefine the treatment of erectile dysfunction. I am excited to contribute to the company’s mission and help drive its success.”

Rodrigo Fraga, CEO of Comphya, added, “We are honored to welcome Pim van Wesel as an Advisor to our Board of Directors. His vast experience in the life sciences sector, coupled with his strategic mindset and leadership in MedTech, will be instrumental in guiding Comphya through its next phase of growth. We look forward to working closely with him“.

For more information on Comphya’s technology and clinical progress, visit www.comphya.com.

About CaverSTIM

CaverSTIM is the first implantable neurostimulator designed to restore erectile function. This innovative technology is primarily intended for patients who are non-responders to oral medications, such as post- prostatectomy patients. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal. It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection. The IPG is implanted subcutaneously in the lower abdomen and is remotely operated by external controllers. The clinician controller allows the medical expert to adjust and tailor the system parameters to best suit each patient. The patient controller enables the patient to activate the device and deliver electrical stimulation to the cavernous nerves with the aim of restoring their function.

About Comphya SA

Comphya is a medical device company based in Lausanne, Switzerland, developing CaverSTIM, the first implantable device to restore erectile function in patients non-responsive to oral drugs. Today, these patients resort to intrapenile injections or penile implants, the only available yet painful, problematic, and outdated therapies. Comphya’s patented solution offers a unique and superior treatment for erectile dysfunction. The company’s goal is to offer physiological sexual function and quality of life to large parts of the male population in great need.

For more information, visit www.comphya.com

Contact

Comphya SA
Rodrigo Fraga-Silva, PhD
CEO & co-founder

Rodrigo.Fraga@comphya.com